Germany is ranked second in the world’s leading medical biotechnology nations and has the largest number of biotech companies within Europe, a world-class research infrastructure and internationally renowned scientists.
Jump into an international medical biotechnology hub
- Germany is ranked second in the world’s leading medical biotechnology nations (the USA is first).
- Germany has the largest number of biotech companies within Europe, a world-class research infrastructure and internationally renowned scientists.
- The main objectives of the industry are the development of drugs and new diagnostic methods, with almost 50% dedicated to health and medicine. The other 50% of companies are divided between agricultural biotechnology (4.2%), industrial biotechnology (10.5%), bioinformatics (4.3%), and companies which offer non-specific services (33.2%).
- In 2011, there were 552 dedicated biotech companies (an increase of 2.6%), which means these firms were mostly occupied with modern biotechnology methods last year. An additional 126 companies used biotechnology as one component of their activities.
- The dedicated biotech companies recorded a turnover of A$bn 3.3 in 2011 (an increase of 10%).
Sell your technology to a very dynamic market
- The average German biotechnology company is only 10 years old. The majority of companies are SMEs, with only eight companies employing more than 250 people.
- Dedicated biotech companies spent A$bn 1.24 on R&D during 2011, the fourth largest investment in the world. Public research institutes active in biotechnology received funding of A$bn 4.3 in 2010, which demonstrates just how important this field is to the future.
- Despite the contraction in investment, down to A$m 238 in 2011 from A$m 891.8 in 2010, the prevalence of biotechnological applications caused overall turnover to continue to rise.
- Medical biotech company revenue (2007-2010) increased by nearly 20%.
- The biopharmaceuticals market recorded sales in 2010 that were 8% higher than the previous year, for a total of A$bn 6.6.
Opportunities for Australian companies
- 516 biopharmaceuticals are currently in clinical development in Germany. The main focus is on monoclonal antibodies with 242 projects.
- Molecular diagnostics has 10% of the German in vitro diagnostics (IVD) market, which is the largest in Europe, and enjoys a growth rate of more than twice that of the rest of the IVD market.
- There is a growing demand for biotechnological techniques and innovations from companies in the chemical, energy, and food manufacturing industries. These interests are derived from a goal to develop more novel and sustainable products and production processes and are supported by the government’s bioeconomy strategy. The changes to the German energy policy and the increasing costs of the public health system mean that innovative biotech solutions are also in much higher demand in these industries.
- Biotechnology companies are forming relationships with industry partners from around the world.
- Meet the unfulfilled demand for biotechnological innovations in the chemical, food production, and energy industries. Receive support from the federal government through the “National Research Strategy BioEconomy 2030”, which has made around A$bn 10 available in the form of subsidies.
- Participate in Biotechnica, the number one event in Europe for Biotechnology, Life Sciences and Lab Technology. It is held every year around October in Hannover and in 2011 saw 11,000 visitors over the three days fair.
To make it in Germany it is of utmost importance to visit or exhibit at trade shows or congresses. Contact us to see how Exportia can help you meet the right person at Medica (usually held in November) or at Biotechnica (usually held in October).
Germany Trade and Invest: www.gtai.de
Bundesministerium für Bildung und Forschung (BMBF): www.bmbf.de
Biotechnologie in Deutschland: www.biotechnologie.de
Exchange rate used: 1€ = A$1.274